Jim Cullen
Cullen Value Fund
Jim Cullen GlaxoSmithKline PLC ADR stake
total: 74
Cullen Value Fund GSK trades
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Reduced:
- 2
- Held since:
- 2019 Q3
- Held for:
- 9 quarters
- Latest activity:
- 2021 Q4
According to 2026 Q1 report, Jim Cullen doesn't hold any GlaxoSmithKline PLC ADR (GSK) shares. To date, the estimated cost basis is nearly $53.35 for "buy" trades and estimated average "sell" price is $50.61. Cullen Value Fund first purchased GSK in 2019 Q3, initially acquiring 18,880 shares. Since the initial investment in GlaxoSmithKline PLC ADR (GSK), Cullen Value Fund has made 3 more transactions.
When did Jim Cullen sell GlaxoSmithKline PLC ADR (GSK)?
Jim Cullen sold off the entire GlaxoSmithKline PLC ADR (GSK) position in 2021 Q4.
When did Jim Cullen buy GlaxoSmithKline PLC ADR (GSK)?
Jim Cullen first invested in GlaxoSmithKline PLC ADR (GSK) in 2019 Q3 at the reported quarter-end price of $53.35 per share.
What's the cost basis of Cullen Value Fund's GSK stake?
The estimated cost basis for GlaxoSmithKline PLC ADR (GSK) stake is around $53.35 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $53.35
- Weighted AVG sell price:
- $50.61
Jim Cullen's historical trades in GlaxoSmithKline PLC ADR
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q4
|
0.00%
|
0
|
$47.76
|
|
-100% (-11,040)
|
-1.96%
|
|
2020 Q4
|
2.05%
|
$46.00
|
-18.70% (-2,540)
|
|||
|
2019 Q4
|
2.66%
|
$58.74
|
-28.07% (-5,300)
|
|||
|
2019 Q3
|
2.59%
|
$53.35
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.